Early postinduction intensification therapy is essential in childhood acute lymphoblastic leukemia
Günter Henze
Correspondence Department of Pediatric Oncology/Hematology, Otto Heubner Center for Pediatrics and Adolescent Medicine, Campus Virchow-Klinikum, Charité University Hospital, Augustenburger Platz 1, D-13353 Berlin, Germany
Email guenter.henze@charite.de
Postinduction intensification therapy (PII) has been key to success in the treatment of many types of childhood cancer and has led to an increase in cure rates during the past 3 decades. This Practice Point commentary discusses the recent findings of the Children's Cancer Group CCG-1961 study, which enrolled 2,078 children and adolescents with acute lymphoblastic leukemia. Patients with rapid marrow response to induction therapy were randomly allocated in a 2 
2 factorial trial to receive either longer or increased intensity PII. A clear advantage—9% improved event-free survival and 6% improved overall survival at 5 years—was shown for more-intensive but not for longer PII; however, a high incidence of osteonecrosis and an increased rate of infections were observed in rapid early responders. This commentary emphasizes the need to balance the beneficial effects of PII in terms of disease control against the possibility of potentially debilitating late adverse sequelae.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.